Trial Profile
Nucala Subcutaneous Injection Special Drug Use Investigation (Long-Term)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 22 Jul 2019 Planned End Date changed from 31 May 2023 to 31 Jan 2024.
- 22 Jul 2019 Planned primary completion date changed from 1 May 2023 to 31 Jan 2024.
- 01 Feb 2017 New trial record